Elan shares take further hit amid fresh Tysabri concerns
02/06/2005 - 12:25:57Share prices in the Irish-based pharmaceutical company Elan fell further on the Dublin stock exchange today amid fresh fears about the multiple sclerosis drug Tysabri.
The fall followed concerns that a fourth patient in the United States may have contracted the potentially fatal brain disease PML after being treated with Tysabri.
Sales of the drug were halted in February after a patient died from PML.
